Literature DB >> 25837686

Selective histone deacetylase 6 inhibition prolongs survival in a lethal two-hit model.

Xin Cheng1, Zhengcai Liu2, Baoling Liu1, Ting Zhao1, Yongqing Li1, Hasan B Alam3.   

Abstract

BACKGROUND: Hemorrhagic shock (HS) followed by a subsequent insult ("second hit") often initiates an exaggerated systemic inflammatory response and multiple organ failure. We have previously demonstrated that valproic acid, a pan histone deacetylase inhibitor, could improve survival in a rodent "two-hit" model. In the present study, our goal was to determine whether selective inhibition of histone deacetylase 6 with Tubastatin A (Tub-A) could prolong survival in a two-hit model where HS was followed by sepsis from cecal ligation and puncture (CLP).
METHODS: C57Bl/6J mice were subjected to sublethal HS (30% blood loss) and then randomly divided into two groups (n = 13 per group) such as Tub-A group (treatment) and vehicle (VEH) group (control). The Tub-A group was given an intraperitoneal injection of Tub-A (70 mg/kg) dissolved in dimethyl sulfoxide (DMSO). The VEH group was injected with DMSO (1 μl/g body weight). After 24 h, all mice were subjected CLP followed immediately by another dose of Tub-A or DMSO. Survival was monitored for 10 d. In a parallel study, peritoneal irrigation fluid and liver tissue from Tub-A- or DMSO-treated mice were collected 3 h after CLP. Enzyme-linked immunosorbent assay was performed to quantify activity of the myeloperoxidase and concentrations of tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6) in the peritoneal irrigation fluid. RNA was isolated from the liver tissue, and real-time polymerase chain reaction was performed to measure relative messenger RNA levels of TNF-α and IL-6.
RESULTS: Treatment with Tub-A significantly improved survival compared with that of the control (69.2% versus 15.4%). In addition, Tub-A significantly suppressed myeloperoxidase activity (169.9 ± 8.4 ng/mL versus 70.4 ± 17.4 ng/mL; P < 0.01) and reduced levels of cytokines TNF-α and IL-6 in the peritoneal fluid (TNF-α: 105.7 ± 4.7 versus 7.4 ± 2.4 pg/mL; IL-6: 907.4 ± 2.3 versus 483.6 ± 1.6 pg/mL; P < 0.01) compared with those in the VEH control. Gene expression measured by real-time polymerase chain reaction confirmed that Tub-A inhibits transcription of TNF-α and IL-6.
CONCLUSIONS: Tub-A treatment significantly improves survival, attenuates inflammation, and downregulates TNF-α and IL-6 gene expression in a rodent two-hit model.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HDAC6; Hemorrhagic shock; Mouse; Tubastatin A; Two-hit

Mesh:

Substances:

Year:  2015        PMID: 25837686      PMCID: PMC4606460          DOI: 10.1016/j.jss.2015.02.070

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  28 in total

Review 1.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

2.  Effect of different resuscitation strategies on neutrophil activation in a swine model of hemorrhagic shock.

Authors:  Hasan B Alam; Kathleen Stanton; Elena Koustova; David Burris; Norman Rich; Peter Rhee
Journal:  Resuscitation       Date:  2004-01       Impact factor: 5.262

Review 3.  Evolving concepts in the pathogenesis of postinjury multiple organ failure.

Authors:  F A Moore; E E Moore
Journal:  Surg Clin North Am       Date:  1995-04       Impact factor: 2.741

4.  Pharmacologic resuscitation: cell protective mechanisms of histone deacetylase inhibition in lethal hemorrhagic shock.

Authors:  Muhammad U Butt; Elizabeth A Sailhamer; Yongqing Li; Baoling Liu; Fahad Shuja; George C Velmahos; Marc DeMoya; David R King; Hasan B Alam
Journal:  J Surg Res       Date:  2009-05-13       Impact factor: 2.192

5.  PI3-kinase and PDK-1 regulate HDAC1-mediated transcriptional repression of transcription factor NF-kappaB.

Authors:  Yong Seok Choi; Sunjoo Jeong
Journal:  Mol Cells       Date:  2005-10-31       Impact factor: 5.034

6.  A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.

Authors:  Yih Lin Chung; Ming Yuan Lee; Ae June Wang; Lin Fen Yao
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

Review 7.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

Review 8.  HDAC family: What are the cancer relevant targets?

Authors:  Olaf Witt; Hedwig E Deubzer; Till Milde; Ina Oehme
Journal:  Cancer Lett       Date:  2008-09-27       Impact factor: 8.679

Review 9.  Timing and volume of fluid administration for patients with bleeding.

Authors:  I Kwan; F Bunn; I Roberts
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Immunodesign of experimental sepsis by cecal ligation and puncture.

Authors:  Daniel Rittirsch; Markus S Huber-Lang; Michael A Flierl; Peter A Ward
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

View more
  10 in total

Review 1.  Histone Deacetylase Inhibitors: A Novel Strategy in Trauma and Sepsis.

Authors:  Aaron M Williams; Isabel S Dennahy; Umar F Bhatti; Ben E Biesterveld; Nathan J Graham; Yongqing Li; Hasan B Alam
Journal:  Shock       Date:  2019-09       Impact factor: 3.454

2.  Histone Deacetylase 6 Regulates Bladder Architecture and Host Susceptibility to Uropathogenic Escherichia coli.

Authors:  Adam J Lewis; Bijaya K Dhakal; Ting Liu; Matthew A Mulvey
Journal:  Pathogens       Date:  2016-02-14

3.  HDAC6 inhibition prevents TNF-α-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions.

Authors:  Jinyan Yu; Mengshi Ma; Zhongsen Ma; Jian Fu
Journal:  Oncotarget       Date:  2016-08-23

4.  Protective effect of Cl-amidine against CLP-induced lethal septic shock in mice.

Authors:  Ting Zhao; Baihong Pan; Hasan B Alam; Baoling Liu; Roderick T Bronson; Qiufang Deng; Erxi Wu; Yongqing Li
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

Review 5.  Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury.

Authors:  Zachary Pickell; Aaron M Williams; Hasan B Alam; Cindy H Hsu
Journal:  J Am Heart Assoc       Date:  2020-05-22       Impact factor: 5.501

Review 6.  Epigenetics in Sepsis: Understanding Its Role in Endothelial Dysfunction, Immunosuppression, and Potential Therapeutics.

Authors:  Deborah Cross; Ruth Drury; Jennifer Hill; Andrew J Pollard
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

7.  Systematic review and meta-analysis of experimental studies evaluating the organ protective effects of histone deacetylase inhibitors.

Authors:  Syabira I Yusoff; Marius Roman; Florence Y Lai; Bryony Eagle-Hemming; Gavin J Murphy; Tracy Kumar; Marcin Wozniak
Journal:  Transl Res       Date:  2018-11-22       Impact factor: 10.171

Review 8.  Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease.

Authors:  Ibtisam Mumtaz; Mir Owais Ayaz; Mohamad Sultan Khan; Umar Manzoor; Mohd Azhardin Ganayee; Aadil Qadir Bhat; Ghulam Hassan Dar; Badrah S Alghamdi; Anwar M Hashem; Mohd Jamal Dar; Gulam Md Ashraf; Tariq Maqbool
Journal:  Front Aging Neurosci       Date:  2022-09-07       Impact factor: 5.702

Review 9.  The therapeutic potential of epigenetic manipulation during infectious diseases.

Authors:  Joby Cole; Paul Morris; Mark J Dickman; David H Dockrell
Journal:  Pharmacol Ther       Date:  2016-08-09       Impact factor: 12.310

Review 10.  Targeted inhibition of histone deacetylase 6 in inflammatory diseases.

Authors:  Jie Ran; Jun Zhou
Journal:  Thorac Cancer       Date:  2019-01-21       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.